Preprint
Oct 2026
A model-assisted design for phase I oncology drug combination trials incorporating backfill
Historically, phase I oncology trials were designed with the focus to find the highest tolerable dose. However, given the FDA's acknowledgment that the highest tolerable dose might not be the dose which is optimal biologically, there is an increased emphasis the development of designs that explore the dose-toxicity and...
Connor Celum, Evan M. Bagley Statistics Department, California State University et al.
· 0 citations